On the use of solid 133Ba sources as surrogate for liquid 131I in SPECT/CT calibration: a European multi-centre evaluation
-
Published:2023-11-23
Issue:1
Volume:10
Page:
-
ISSN:2197-7364
-
Container-title:EJNMMI Physics
-
language:en
-
Short-container-title:EJNMMI Phys
Author:
Tran-Gia JohannesORCID, Denis-Bacelar Ana M., Ferreira Kelley M., Robinson Andrew P., Bobin Christophe, Bonney Lara M., Calvert Nicholas, Collins Sean M., Fenwick Andrew J., Finocchiaro Domenico, Fioroni Federica, Giannopoulou Katerina, Grassi Elisa, Heetun Warda, Jewitt Stephanie J., Kotzasarlidou Maria, Ljungberg Michael, Lourenço Valérie, McGowan Daniel R., Mewburn-Crook Jamie, Sabot Benoit, Scuffham James, Sjögreen Gleisner Katarina, Solc Jaroslav, Thiam Cheick, Tipping Jill, Wevrett Jill, Lassmann Michael,
Abstract
Abstract
Introduction
Commissioning, calibration, and quality control procedures for nuclear medicine imaging systems are typically performed using hollow containers filled with radionuclide solutions. This leads to multiple sources of uncertainty, many of which can be overcome by using traceable, sealed, long-lived surrogate sources containing a radionuclide of comparable energies and emission probabilities. This study presents the results of a quantitative SPECT/CT imaging comparison exercise performed within the MRTDosimetry consortium to assess the feasibility of using 133Ba as a surrogate for 131I imaging.
Materials and methods
Two sets of four traceable 133Ba sources were produced at two National Metrology Institutes and encapsulated in 3D-printed cylinders (volume range 1.68–107.4 mL). Corresponding hollow cylinders to be filled with liquid 131I and a mounting baseplate for repeatable positioning within a Jaszczak phantom were also produced. A quantitative SPECT/CT imaging comparison exercise was conducted between seven members of the consortium (eight SPECT/CT systems from two major vendors) based on a standardised protocol. Each site had to perform three measurements with the two sets of 133Ba sources and liquid 131I.
Results
As anticipated, the 131I pseudo-image calibration factors (cps/MBq) were higher than those for 133Ba for all reconstructions and systems. A site-specific cross-calibration reduced the performance differences between both radionuclides with respect to a cross-calibration based on the ratio of emission probabilities from a median of 12–1.5%. The site-specific cross-calibration method also showed agreement between 133Ba and 131I for all cylinder volumes, which highlights the potential use of 133Ba sources to calculate recovery coefficients for partial volume correction.
Conclusion
This comparison exercise demonstrated that traceable solid 133Ba sources can be used as surrogate for liquid 131I imaging. The use of solid surrogate sources could solve the radiation protection problem inherent in the preparation of phantoms with 131I liquid activity solutions as well as reduce the measurement uncertainties in the activity. This is particularly relevant for stability measurements, which have to be carried out at regular intervals.
Funder
European Metrology Programme for Innovation and Research National Measurement System of the UK’s Department for Business, Energy and Industrial Strategy Universitätsklinikum Würzburg
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference22 articles.
1. Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16(1):47–59. 2. Tran-Gia J, Denis-Bacelar AM, Ferreira KM, Robinson AP, Calvert N, Fenwick AJ, et al. A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI Phys. 2021;8(1):55. 3. McCready VR. Radioiodine - the success story of Nuclear Medicine : 75th Anniversary of the first use of Iodine-131 in humans. Eur J Nucl Med Mol Imaging. 2017;44(2):179–82. 4. Stokkel MP, HandkiewiczJunak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–28. 5. Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40(7):1126–34.
|
|